Literature DB >> 30332624

Tumor cGAMP Awakens the Natural Killers.

Shriram K Sundararaman1, David A Barbie2.   

Abstract

Type I interferon (IFN) production within the tumor microenvironment is important in shaping the immune response to the tumor. In this issue of Immunity, Marcus et al. (2018) reveal that tumor cells produce 2'3'-cGAMP, which activates the STING pathway in non-tumor cells and leads to type I IFN production and the priming of natural killer cells for tumor rejection.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30332624      PMCID： PMC6390837          DOI： 10.1016/j.immuni.2018.10.001

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  9 in total

1.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.

Authors:  Jesse M Zaretsky; Angel Garcia-Diaz; Daniel S Shin; Helena Escuin-Ordinas; Willy Hugo; Siwen Hu-Lieskovan; Davis Y Torrejon; Gabriel Abril-Rodriguez; Salemiz Sandoval; Lucas Barthly; Justin Saco; Blanca Homet Moreno; Riccardo Mezzadra; Bartosz Chmielowski; Kathleen Ruchalski; I Peter Shintaku; Phillip J Sanchez; Cristina Puig-Saus; Grace Cherry; Elizabeth Seja; Xiangju Kong; Jia Pang; Beata Berent-Maoz; Begoña Comin-Anduix; Thomas G Graeber; Paul C Tumeh; Ton N M Schumacher; Roger S Lo; Antoni Ribas
Journal:  N Engl J Med       Date:  2016-07-13       Impact factor: 91.245

Review 2.  cGAS-STING and Cancer: Dichotomous Roles in Tumor Immunity and Development.

Authors:  Kevin W Ng; Erin A Marshall; John C Bell; Wan L Lam
Journal:  Trends Immunol       Date:  2017-08-19       Impact factor: 16.687

3.  STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.

Authors:  Seng-Ryong Woo; Mercedes B Fuertes; Leticia Corrales; Stefani Spranger; Michael J Furdyna; Michael Y K Leung; Ryan Duggan; Ying Wang; Glen N Barber; Katherine A Fitzgerald; Maria-Luisa Alegre; Thomas F Gajewski
Journal:  Immunity       Date:  2014-11-05       Impact factor: 31.745

4.  Recurrent Loss of STING Signaling in Melanoma Correlates with Susceptibility to Viral Oncolysis.

Authors:  Tianli Xia; Hiroyasu Konno; Glen N Barber
Journal:  Cancer Res       Date:  2016-09-28       Impact factor: 12.701

5.  RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma.

Authors:  Adeline R Lam; Nina Le Bert; David H Raulet; Stephan Gasser; Samantha Sw Ho; Yu J Shen; Li Fm Tang; Gordon M Xiong; John L Croxford; Christine X Koo; Ken J Ishii; Shizuo Akira
Journal:  Cancer Res       Date:  2014-03-03       Impact factor: 12.701

6.  Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence.

Authors:  Selene Glück; Baptiste Guey; Muhammet Fatih Gulen; Katharina Wolter; Tae-Won Kang; Niklas Arndt Schmacke; Anne Bridgeman; Jan Rehwinkel; Lars Zender; Andrea Ablasser
Journal:  Nat Cell Biol       Date:  2017-07-31       Impact factor: 28.824

7.  Viruses transfer the antiviral second messenger cGAMP between cells.

Authors:  A Bridgeman; J Maelfait; T Davenne; T Partridge; Y Peng; A Mayer; T Dong; V Kaever; P Borrow; J Rehwinkel
Journal:  Science       Date:  2015-07-30       Impact factor: 47.728

8.  Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer.

Authors:  Qing Chen; Adrienne Boire; Xin Jin; Manuel Valiente; Ekrem Emrah Er; Alejandro Lopez-Soto; Leni Jacob; Ruzeen Patwa; Hardik Shah; Ke Xu; Justin R Cross; Joan Massagué
Journal:  Nature       Date:  2016-05-18       Impact factor: 49.962

9.  Resistance to checkpoint blockade therapy through inactivation of antigen presentation.

Authors:  Moshe Sade-Feldman; Yunxin J Jiao; Jonathan H Chen; Michael S Rooney; Michal Barzily-Rokni; Jean-Pierre Eliane; Stacey L Bjorgaard; Marc R Hammond; Hans Vitzthum; Shauna M Blackmon; Dennie T Frederick; Mehlika Hazar-Rethinam; Brandon A Nadres; Emily E Van Seventer; Sachet A Shukla; Keren Yizhak; John P Ray; Daniel Rosebrock; Dimitri Livitz; Viktor Adalsteinsson; Gad Getz; Lyn M Duncan; Bo Li; Ryan B Corcoran; Donald P Lawrence; Anat Stemmer-Rachamimov; Genevieve M Boland; Dan A Landau; Keith T Flaherty; Ryan J Sullivan; Nir Hacohen
Journal:  Nat Commun       Date:  2017-10-26       Impact factor: 14.919
  9 in total
  7 in total

Review 1.  Nanovaccines for cancer immunotherapy.

Authors:  Yu Zhang; Shuibin Lin; Xiang-Yang Wang; Guizhi Zhu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-06-06

2.  Improving STING Agonist Delivery for Cancer Immunotherapy Using Biodegradable Mesoporous Silica Nanoparticles.

Authors:  Kyung Soo Park; Cheng Xu; Xiaoqi Sun; Cameron Louttit; James J Moon
Journal:  Adv Ther (Weinh)       Date:  2020-07-21

Review 3.  Inflammatory signaling in genomically instable cancers.

Authors:  Francien Talens; Marcel A T M Van Vugt
Journal:  Cell Cycle       Date:  2019-07-10       Impact factor: 4.534

Review 4.  STING activation in cancer immunotherapy.

Authors:  Ting Su; Yu Zhang; Kristoffer Valerie; Xiang-Yang Wang; Shuibin Lin; Guizhi Zhu
Journal:  Theranostics       Date:  2019-10-15       Impact factor: 11.556

Review 5.  Nanovaccines for Cancer Prevention and Immunotherapy: An Update Review.

Authors:  Xingliang Fang; Huanrong Lan; Ketao Jin; Daojun Gong; Jun Qian
Journal:  Cancers (Basel)       Date:  2022-08-09       Impact factor: 6.575

Review 6.  Regulation of cGAS-Mediated Immune Responses and Immunotherapy.

Authors:  Abdullah F U H Saeed; Xinglin Ruan; Hongxin Guan; Jingqian Su; Songying Ouyang
Journal:  Adv Sci (Weinh)       Date:  2020-02-06       Impact factor: 16.806

7.  Tumor-Derived cGAMP Regulates Activation of the Vasculature.

Authors:  Marco Campisi; Shriram K Sundararaman; Sarah E Shelton; Erik H Knelson; Navin R Mahadevan; Ryohei Yoshida; Tetsuo Tani; Elena Ivanova; Israel Cañadas; Tatsuya Osaki; Sharon Wei Ling Lee; Tran Thai; Saemi Han; Brandon P Piel; Sean Gilhooley; Cloud P Paweletz; Valeria Chiono; Roger D Kamm; Shunsuke Kitajima; David A Barbie
Journal:  Front Immunol       Date:  2020-09-04       Impact factor: 7.561
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.